Diphtheria toxoid ≥30 IU; tetanus toxoid ≥40 IU; Bordetella pertussis antigens: Pertussis toxoid 25 mcg, filamentous haemagglutinin 25 mcg; inactivated poliovirus: Type 1 (Mahoney) 40 D-antigen units, type 2 (MEF-1) 8 D-antigen units, type 3 (Saukett) 32 D-antigen units; H. influenzae type b polysaccharide (polyribosylribitol phosphate) 10 mcg, conjugated to tetanus protein 18-30 mcg
Indications/Uses
Protection against diphtheria, tetanus, pertussis, poliomyelitis & against invasive infections due to H. influenzae type b (eg, meningitis, blood poisoning) in childn ≥2 mth.
IM 2 inj w/ an interval of 2 mth, 1 at the age of 2 mth & 1 at the age of 4 mth followed by a booster inj at the age of 11 mth, or, 3 inj at an interval of 1-2 mth from the age of 2 mth, followed by a booster inj w/in the 2nd yr of life.
Hypersensitivity to glutaraldehyde, neomycin, streptomycin or polymyxin B, to a pertussis vaccine (acellular or whole cell). Allergic reaction after a previous inj of vaccine. Childn w/ evolving encephalopathy, or encephalopathy w/in 7 days of a previous dose of pertussis vaccine. Postpone vaccination in case of febrile or acute disease.
Blood disorders eg, thrombocytopenia or clotting disorders. Presented w/ febrile convulsion. Fever ≥40°C, collapse or shock-like state w/ hypotonic-hyporesponsive episode, persistent, inconsolable crying lasting ≥3 hr w/in 48 hr vaccination, convulsions (w/ or w/o fever) w/in 3 days of vaccination. Guillain-Barre syndrome or brachial neuritis. Concomitant use w/ corticosteroids, cytotoxic drugs, radiotherapy or other drugs that may weaken the immune system.
Sign Out
6127cc01-1d9c-4fae-9749-a5b500d2479b.GIF)
